ecancermedicalscience

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

26 Nov 2014
Pan Pantziarka, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, Vikas P Sukhatme

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Article metrics: 42999 views
9389
33610

Related Articles

Michael Retsky, Romano Demicheli, William Hrushesky, Ted James, Rick Rogers, Michael Baum, Jayant S Vaidya, Osaro Erhabor, Patrice Forget
Luis Larrea, Enrique López, Paola Antonini, Verónica González, Miguel Ángel Berenguer, Maria Carmen Baños, Jose Bea, Jose Domingo
Antonio Augusto Claudio Pereira, Mayara Maria de Jesus Rozante, Rafael Bauer Doveinis, Carmine Porcelli Salvarani, Tania Hissa Anegawa, Paola da Costa Souza, Daniel J Brat, Alessandra Cristina de Oliveira Borges
Rachel P Riechelmann, Renata D’Alpino Peixoto, Gustavo Dos Santos Fernandes, Rui F Weschenfelder, Gabriel Prolla, Duilio Rocha Filho, Aline Chaves Andrade, Marcela Crosara, Juliana Florinda M Rego, Rene C Gansl, Felipe Coimbra, Samuel Aguiar Jr, Elisângela Carvalho, Paulo M Hoff, Anelisa K Coutinho
Ryan M Kahn, Sushmita Gordhandas, Kiersten Craig, Tanaka K Dune, Kevin Holcomb, Eloise Chapman-Davis, Melissa K Frey